Literature DB >> 19708858

The human urocortin 2 gene is regulated by hypoxia: identification of a hypoxia-responsive element in the 3'-flanking region.

Katrin Bühler1, Isabelle Plaisance, Thomas Dieterle, Marijke Brink.   

Abstract

Ucn2 (urocortin 2) has been shown to exert potent beneficial effects in the cardiovascular system, including inhibition of apoptosis, improvement of cardiomyocyte contractility and decrease of oxidative stress. The mechanisms that contribute to the regulation of hUcn2 (human Ucn2) expression in cardiovascular pathologies are not known. In the present study, we analysed the mechanism by which hypoxia, a major stimulus in ischaemic heart disease, regulates Ucn2 gene expression. Hypoxia and CPX (ciclopirox olamine), which prevents proteolytic degradation of HIF (hypoxia-inducible factor), significantly increased hUcn2 mRNA levels in TE-671 cells. Gene silencing of endogenous HIF1alpha abolishes this increase. Hypoxia and CPX activated a luciferase-linked fragment of the 3'FLR (3'-flanking region) of the hUcn2 gene containing two putative HREs (hypoxia-response elements), HRE1 and HRE2. Site-directed mutagenesis experiments demonstrated that HRE1 is required for HIF1alpha-dependent luciferase activation. This activation was conserved in constructs with the 3'FLR fragment placed upstream of the luciferase gene, indicating an enhancer function for HRE1. Competition assays revealed direct binding between HRE1 and HIF1alpha. Regulation of Ucn2 by hypoxia was confirmed in rat neonatal cardiomyocytes and in cardiac-derived H9c2 cells transfected with constructs of the 3'FLR of the hUcn2 gene. In conclusion, our study demonstrates that hypoxia induces hUcn2 expression via a specific HRE in the 3'FLR of the hUcn2 gene, which interacts with the transcription factor HIF1alpha. Hypoxia-mediated stimulation of cardioprotective Ucn2 may help to preserve cardiac function and prevent apoptosis in ischaemic conditions in the heart.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19708858     DOI: 10.1042/BJ20090311

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  9 in total

1.  Targeted genes and interacting proteins of hypoxia inducible factor-1.

Authors:  Wei Liu; Shao-Ming Shen; Xu-Yun Zhao; Guo-Qiang Chen
Journal:  Int J Biochem Mol Biol       Date:  2012-05-31

Review 2.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses.

Authors:  Tao Shen; Shile Huang
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

3.  CRF and urocortin 3 protect the heart from hypoxia/reoxygenation-induced apoptosis in zebrafish.

Authors:  Tegan A Williams; Jillian C Bergstrome; Juliana Scott; Nicholas J Bernier
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-05-24       Impact factor: 3.619

4.  Posttranslational processing of human and mouse urocortin 2: characterization and bioactivity of gene products.

Authors:  Joan M Vaughan; Cynthia J Donaldson; Wolfgang H Fischer; Marilyn H Perrin; Jean E Rivier; Paul E Sawchenko; Wylie W Vale
Journal:  Endocrinology       Date:  2013-03-14       Impact factor: 4.736

5.  Endometriosis, a disease of the macrophage.

Authors:  Annalisa Capobianco; Patrizia Rovere-Querini
Journal:  Front Immunol       Date:  2013-01-28       Impact factor: 7.561

6.  Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system.

Authors:  Kazuhiro Takahashi
Journal:  Int J Endocrinol       Date:  2012-05-17       Impact factor: 3.257

Review 7.  Reposition of the Fungicide Ciclopirox for Cancer Treatment.

Authors:  Zhu Huang; Shile Huang
Journal:  Recent Pat Anticancer Drug Discov       Date:  2021       Impact factor: 3.038

Review 8.  The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective.

Authors:  Parviz Mammadzada; Pablo M Corredoira; Helder André
Journal:  Cell Mol Life Sci       Date:  2019-12-31       Impact factor: 9.261

9.  Repurposing antimycotic ciclopirox olamine as a promising anti-ischemic stroke agent.

Authors:  Hongxuan Feng; Linghao Hu; Hongwen Zhu; Lingxue Tao; Lei Wu; Qinyuan Zhao; Yemi Gao; Qi Gong; Fei Mao; Xiaokang Li; Hu Zhou; Jian Li; Haiyan Zhang
Journal:  Acta Pharm Sin B       Date:  2019-08-14       Impact factor: 11.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.